50 results about "Low density lipoprotein cholesterol level" patented technology

Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained period of time to lower total cholesterol levels; to lower LDL-cholesterol levels; to lower triglyceride levels; to treat dyslipidemia; to treat and slow the progression of atherosclerosis; and to treat, prevent, and reduce the risk of heart attacks and strokes in patients. In the pharmaceutical formulations and methods of the invention, the exendin may be exendin-4, an exendin-4 agonist, or an exendin-4 analog agonist. The pharmaceutical formulations may be polymer-based pharmaceutical formulations that may be administered once weekly. An exemplary pharmaceutical formulation comprises 5% (w / w) of exenatide, about 2% (w / w) of sucrose, and about 93% (w / w) of a poly(lactide-co-glycolide) polymer, wherein the poly(lactide-co-glycolide) polymer is in the form of microshperes encapsulating the exenatide.

Controlled studies demonstrate that products and related methods using soy related peptides lower total and LDL cholesterol levels in individuals. In one exemplary embodiment of the present disclosure, a product containing an effective amount of lunasin peptides that lowers cholesterol levels in an individual that consumes the lunasin peptides is provided. In another exemplary embodiment of the present disclosure, a composition containing an effective amount of lunasin peptides or lunasin peptide derivatives and one or more enzyme inhibitors is provided. In a related exemplary embodiment of the present disclosure, a method for lowering or reducing cholesterol levels in an individual is provided where a product containing an effective amount of lunasin peptides to an individual is provided and a claim that the product lowers or reduces cholesterol, total cholesterol, LDL cholesterol or lipid levels in an individual that consumes the composition is made.

The invention relates to a method for treating Syndrome X, or inhibiting the onset of symptoms of Syndrome X in a patient, and includes administering a therapeutically effective amount of a salt of at least one alkylated and cross-linked polymer, or a copolymer thereof, the polymer salt formed as a product of the reaction of one or more polymers, or salts and copolymers thereof, having a repeat unit that is essentially: where n is a positive integer and each R, independently, is H or a C1-C8 alkyl group; at least one aliphatic alkylating agent; and a cross-linking agent. Long term administration of the cross-linked polyamine salts of the invention increases HDL levels and decreases LDL levels in patients. The invention also provides for administration of the polymer salt colesevelam, in combination with an HMG-CoA reductase inhibitor; the combined administration is effective in further lowering serum total-cholesterol and LDL-cholesterol levels beyond that achieved by either agent alone.

A food product suitable for reducing low density lipoprotein cholesterol levels comprising an amount of soy protein of at least 5 grams per average serving and at least 5 mg / kg statins is described. Preferably the food product comprises a fermented soy ingredient.

A method for measuring LDL cholesterol in a sample using a test piece is provided which involves a step of measuring the total cholesterol in the sample; a step of measuring the non-LDL cholesterol in the sample; and a step of subtracting the non-LDL cholesterol value from the total-cholesterol value to obtain the LDL cholesterol level.

The invention discloses the drug application of epimedin C for treating diabetic liver injury, and belongs to the technical field of biomedicine. The present invention discloses for the first time that epimedin C can increase the level of high-density lipoprotein cholesterol in the liver of diabetic model animals, reduce the level of low-density lipoprotein cholesterol in the liver, alleviate the problem of lipid metabolism disorder, reduce liver index, and enhance superoxide dismutase in the liver , Glutathione peroxidase activity, reduce malondialdehyde content, improve liver oxidative stress state, maintain normal shape and structure of liver cells and tissues, reduce liver alanine aminotransferase and aspartate aminotransferase activity levels, and promote liver function repair, Therefore, it can be used to prepare medicines for treating diabetic liver damage. Epimedin C prepares a medicine for treating diabetic liver damage and uses it in the form of pharmaceutical preparations, including buccal tablets, coated tablets and hard capsules. The invention provides a basis for the treatment of diabetic liver damage, and also provides ideas for the deep development and utilization of epimedium resources.

The present invention relates to the use of a CD24 protein for lowering low-density lipoprotein cholesterol levels, treating and preventing atherosclerosis, and for reducing risk of cardiovascular disease.

This invention is related to the field of hypercholesterolemia. In particular, the invention provides compositions and methods to modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9 using synthetic ligands and / or synthetic ligand derivative sequences of 3-8 amino acids ranging between 350-2,000 Da. Altering the conformation of PCSK9 affects the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for ligands which can raise LDL levels.

Controlled studies demonstrate that products and related methods using soy related peptides lower total and LDL cholesterol levels in individuals. In one exemplary embodiment of the present disclosure, a product containing an effective amount of lunasin peptides that lowers cholesterol levels in an individual that consumes the lunasin peptides is provided. In another exemplary embodiment of the present disclosure, a composition containing an effective amount of lunasin peptides or lunasin peptide derivatives and one or more enzyme inhibitors is provided. In a related exemplary embodiment of the present disclosure, a method for lowering or reducing cholesterol levels in an individual is provided where a product containing an effective amount of lunasin peptides to an individual is provided and a claim that the product lowers or reduces cholesterol, total cholesterol, LDL cholesterol or lipid levels in an individual that consumes the composition is made.

The invention discloses applications of eleven-component golden pills in preparation of a medicine treating hyperlipemia. Animal experiments prove that eleven-component golden pills have substantial treatment effects on experiment mouse hyperlipidemia models, cholesterol, triglyceride and low-density lipoprotein cholesterol levels in blood plasma can be lowered substantially (P is less than 0.01), and lowering effects on part of blood lipid indexes in a high-dosage group is even better than effects of a control medicine. Clinic experiments show that the total clinic effective rate of a treatment group is 91.31%, blood lipid indexes of TC, TG, LDL-C and the like are lowered substantially, HDL-C is raised substantially, and the treatment group is better than the control group in improvement of TC (P is less than 0.05), which show that there is no difference between the eleven-component golden pills and a conventional lipid lowering medicine simvastatin tablets in improvement effects on blood lipid indexes of TG, LDL-C, HDL-C and the like, but the eleven-component golden pills are better than simvastatin tablets in improvement of TC.

The present invention provides functional genetic variation of genes related to LDL-C levels and related applications; specifically, the present invention provides detection of the following protein amino acid sites and / or their corresponding gene sites in a sample from an individual to be tested The application of reagent materials and / or instruments and equipment in the preparation of a detection system for evaluating blood lipid levels, dyslipidemia and / or risk of coronary heart disease: EV15 gene rs117711462, APOB gene rs376825639 and / or PKD1L3 gene rs17358402 respectively cause EVI5 protein Amino acid 354, amino acid 3768 of APOB protein, and / or amino acid 1572 of PKD1L3 protein code change. Individuals with EVI5Arg354Cys and / or PKD1L3Arg1572His mutations have higher total cholesterol and / or low-density lipoprotein cholesterol levels and / or higher risk of dyslipidemia. Individuals with APOBIle3768Thr mutation have lower low-density lipoprotein cholesterol level, lower risk of dyslipidemia and / or lower risk of coronary heart disease.

Application of the pigeon pea ketonic acid A and a pharmaceutically acceptable derivative thereof in preparation of a medicine for a diabetes-accompanying disease or hyperlipidemia as well as a functional health product. The diabetes-accompanying disease is hyperlipidemia, liver damage, kidney damage, or pancreas damage accompanying diabetes.

The present invention provides methods and compositions for treating arteriosclerotic vascular diseases by cyclohexenone compounds. In some embodiments, the compound in the methods inhibits PDGF-stimulated smooth muscle cell proliferation or migration. In some embodiments, the atherosclerosis is associated with coronary artery disease, aneurysm, arteriosclerosis, myocardial infarction, embolism, stroke, thrombosis, angina, vascular plaque inflammation, vascular plaque rupture, Kawasaki disease, calcification or inflammation. In some embodiments, the compound lowers low-density lipoprotein (LDL) cholesterol in the subject. In some embodiments, the compound maintains a normal low-density lipoprotein (LDL) cholesterol level in the subject.